Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer - Kumar Prabhash; Roshan Pawar; Vijaya Gunjal (JCO Global Oncology)